Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

_blank" href= "http://www.yourcanceryourchoice.com/">http://www.yourcanceryourchoice.com. Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

Alimta(R) and Gemzar(R) are registered trademarks of Eli Lilly and Company.

Tarceva(R) is a registered trademark of Genentech.

Taxotere(R) is a registered trademark of Sanofi-Aventis.

NOTE: Other than statements of historical fact, the statements made in this press release about plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to obtain future financing and fund the product development of our pipeline; the possibility that the FDA refuses to approve our NDA; because our Phase 3 clinical trial known as the SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial failed to meet its primary endpoint, the FDA may require additional data, analysis or studies before the NDA is approved by the FDA; the outcome of any discussions with the FDA; the initiation, t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... the third quarter ended September 30, 2014 on Thursday, ... markets. Howard Robin , president and chief executive ... results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. ... and a live audio-only Webcast of the conference call ...
(Date:10/30/2014)... BOTHELL, Wash. , Oct. 30, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s third quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... TUSTIN, Calif., Jan. 6, 2012 Radient Pharmaceuticals Corporation ... Vitro Diagnostic (IVD) cancer tests, today announced that ... will be launched with a print ad that ... throughout 2012.  These journals have high circulation among ...
... WAYNE, N.J., Jan. 6, 2012  Cascade Medical ... proprietary platelet-rich plasma (PRP) and platelet-rich fibrin matrix (PRFM) ... tissue and bone repair, announced the sale of their ... ConMed Linvatec for the worldwide orthopedic, dental, and wound ...
Cached Medicine Technology:Radient Pharmaceuticals Announces New Advertisement for Oncology Publications 2Cascade Medical Enterprises, LLC Announces the Sale of Their Orthopedic Business 2
(Date:10/30/2014)... 2014 Graphics, coding, typography and search ... the craft of web design and require thorough knowledge ... simpler solution to create a website can be as ... information, customer reviews and Facebook posts all accumulate on ... the next evolution of how a business can develop ...
(Date:10/30/2014)... 2014 High efficacy and low ... the medical-grade skin care domain: Cosmederm, the specialty ... potent topical dermatological products, today announces the launch ... with patented COSMEDERM®-7 anti-irritant technology. , Formulated ... and 70%) and a low pH (pH 1.2 ...
(Date:10/30/2014)... October 30, 2014 PreDiabetes Centers ... PreD Store shoppers with a supply of sugardown®, ... to reduce post-meal blood sugar spikes. Learning how to ... an important part of a diabetes prevention plan. , ... receive one complimentary tube of sugardown. The offer expires ...
(Date:10/30/2014)... Radio listeners who indicate use of four ... of traditional radio commercials and have overwhelmingly endorsed custom ... a purchasing decision. , Those are some highlights from ... radio marketing company CRN International. The research is now ... respondents who indicated they have purchased or considered purchase ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, ... genes have been identified that appear linked to autism ... say they are on their way to discovering up ... disorder. Autism spectrum disorders include a range of ... repetitive behaviors. An estimated one in 68 U.S. children ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... by researchers at the University of Southern California suggests that ... found that a storyline on the primetime NBC network drama ... habits had a positive impact on the attitudes and behaviors ... the Sept. 14 Journal of Health Communication and now available ...
... warning, experts say , SATURDAY, Sept. 22 (HealthDay News) ... be so silent, experts say. , That,s why women ... to possible symptoms of ovarian cancer, according to a ... who are trying to increase awareness about the disease. ...
... Sept. 21 We may have worked hard to ... barbecues, beach lounging and,ball games may have taken a ... back into shape and back into the one thing ... report from Kellogg,s at:, http://media.medialink.com/WebNR.aspx?story=33869 Registered journalists ...
... The following is a,statement by Robert Greenstein, ... Priorities, on the new congressional SCHIP agreement:, ... million,low-income uninsured children, a major accomplishment. Contrary to ... would gain coverage are poor,and near-poor children who ...
... it is to persist, experts say, , , FRIDAY, Sept. 21 (HealthDay ... rite of passage. But new research suggests it has a darker ... people who start to drink at a younger age more likely ... be injured, to be in motor vehicle crashes and to be ...
... that a chemical chain reaction that controls organ size ... the difference between normal growth and cancer. The study, ... how organs can grow uncontrollably huge and become cancerous ... chain reaction, a domino-like chain of events we call ...
Cached Medicine News:Health News:ER episode impacts viewers' health knowledge and behavior 2Health News:Pelvic Exams Can Help Spot Ovarian Cancer 2Health News:Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement 2Health News:Teenage Drinking Can Spell Lasting Trouble 2Health News:Teenage Drinking Can Spell Lasting Trouble 3Health News:Controlling for size may also prevent cancer 2
Stainless steel plain Steinman Pins available in point types A through F....
Full pin skeletal traction pins with cove point....
Calibrated Guide Pins have a 12.7 mm calibration and are available in plain, with a threaded tip, or with a trocar point....
Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
Medicine Products: